



GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

Voice : +91-40-2784 9700 / 2784 2602 / 2784 4557

E-mail : info@godavaridrugs.com | Website : www.godavaridrugs.com

14.11.2025

To,
The Manger [Listing]
The BSE Limited
The Secretary, Listing Department
Phirozejeejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001
Scrip code: 530317

Dear Sirs/Madam,

Sub: Submission of Un-Audited Financial Results of the Company and Limited Review Report as per the provisions of Regulation 33 of SEBI (LODR) Regulations, 2015

Please find the enclosed herewith the following documents in terms of Regulation 33 of SEBI (LODR) Regulations, 2015:

1. Un-audited Financial Results of the Company for the quarter and half year ended 30th September, 2025.
2. A certified copy of Limited Review Report on standalone financials for the quarter and half year ended 30th September, 2025 given by the statutory auditors.

These are also being made available on the website of the Company at www.godavaridrugs.com.

The Board Meeting Commenced at 03:30 P.M and concluded at 04:00 PM

Please take the above in your records.

Thanking You,
For Godavari Drugs Limited

Venkatesh Achanta
Company Secretary & Compliance Officer

GODAVARI DRUGS LIMITED

CIN : L24230TG1987PLC008016

Regd Office : "Mayfair", S.P.Road, Seunderabad, 500003

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR SIX MONTHS AND QUARTER ENDED SEPTEMBER 30, 2025

Rs.in Lakhs

Sl. N o.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	2664.94	2381.13	2608.79	5046.07	5829.54	11335.01
2	Other Income	63.54	1.22	0.94	64.76	77.45	97.72
3	Total Revenue from operations (1+2)	2728.48	2382.35	2609.73	5110.83	5906.99	11432.73
4	Expenses						
	(a) Cost of materials consumed	2399.24	1798.93	1697.53	4198.17	4392.36	8523.96
	Changes in inventories of finished goods						
	(b) & work-in-progress	-388.23	-85.41	59.25	-473.64	-294.81	-358.20
	(c) Employee benefits expense	144.28	135.67	137.91	279.95	264.34	502.81
	(d) Depreciation & amortization expense	60.37	60.43	58.22	120.80	113.18	244.76
	(e) Finance Costs	90.84	100.46	107.98	191.30	251.50	473.20
	(f) Other Expenses	309.85	242.04	423.63	551.89	854.00	1483.66
	Total expenses	2616.35	2252.12	2484.52	4868.47	5580.57	10870.19
5	Profit before exceptional Items and tax (3-4)	112.13	130.23	125.21	242.36	326.42	562.54
6	Exceptional items	-	-	-	-	-	-
7	Profit before Tax (5-6)	112.13	130.23	125.21	242.36	326.42	562.54
8	Tax expense	-12.06	-26.17	-16.35	-38.23	-54.48	-124.54
9	Net Profit for the period (7-8)	100.07	104.06	108.86	204.13	271.94	438.00
10	Other Comprehensive Income						-
	Items that will not be reclassified to profit						
	(i) or loss	-	-	-	-	-	-
	(ii) Income tax relating to Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	Items that will be reclassified to profit or						
	(iii) loss	-	-	-	-	-	-
	(iv) Income tax relating to Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)	-	-	-	-	-	-
11	Total Comprehensive Income (9+10)	100.07	104.06	108.86	204.13	271.94	438.00
12	Paid-up equity share capital (Face Value Rs. 10/- per share)	753.05	753.05	753.05	753.05	753.05	753.05
13	Other Equity						3581.56
14	Earnings per share (of Rs. 10/- each) (not annualized)						
	(a) Basic	1.33	1.38	1.45	2.71	3.61	5.82
	(b) Diluted	1.33	1.38	1.45	2.71	3.61	5.82

- The above results , as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on November 14, 2025
- The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable
- The format for un-audited quarterly results as prescribed in SEBI's Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5th July, 2016. Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with IND AS.
- Corresponding figures in previous year / period have been regrouped wherever considered necessary.

For GODAVARI DRUGS LIMITED

Mohit Jain
 Mohit Jain
 Wholetime Director & CFO
 DIN: 03405414

Place: Secunderabad
 Date : 14.11.2025




GODAVARI DRUGS LIMITED
Statement of Assets and Liabilities

Rs.in Lakhs

Sl.No	Particulars	Period ended 30.09.2025 (Unaudited)	Year ended 31.03.2025 (Audited)
A	ASSETS		
1	Non-current assets		
	(a) Property, Plant and Equipment	3141.40	3260.88
	(b) Capital work-in-progress	4088.23	2994.61
	(c) Investment Property		
	(d) Goodwill		
	(e) Other Intangible assets		
	(f) Intangible assets under development		
	(g) Biological Assets other than bearer plant		
	(h) Financial Assets		
	(i) Investments	0.01	0.01
	(ii) Trade Receivables		
	(iii) Loans		
	(iv) Other (to be specified)	177.04	175.84
	(i) Deferred tax assets (net)		
	(j) Other non-current assets		
2	Current assets		
	(a) Inventories	3624.29	2794.13
	(b) Financial Assets		
	(i) Investments		
	(ii) Trade Receivables	4178.81	4232.36
	(iii) Cash and cash equivalents	229.31	237.33
	(iv) Bank balances other than (iii) above		
	(v) Loans	93.30	102.21
	(vi) Other (to be specified)		
	(c) Loans		
	(d) Other current assets	713.98	510.27
	Total Assets	16246.37	14307.64
B	EQUITY AND LIABILITIES		
1	EQUITY		
	(a) Equity Share Capital	753.05	753.05
	(b) Other Equity	3785.68	3581.56
2	LIABILITIES		
I	Non-current assets		
	(a) Financial Liabilities		
	(i) Borrowings	2986.15	2389.52
	(ii) Trade Payable		
	(iii) Other financial liabilities (other than those specified in item (b), to be specified)		
	(b) Provisions	91.35	82.64
	(c) Defferred Tax liabilities (net)	188.64	191.84
	(d) Other non-current liabilities		
II	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	4406.68	3773.25
	(ii) Trade Payable		
	A. Total outstanding dues of microenterprises and small enterprises	28.24	31.59
	B. Total outstanding dues creditors other than of microenterprises and small enterprises	3057.07	2839.01
	(iii) Other financial liabilities (other than those speified in item (c))	789.06	546.15
	B. Other Current liabilities		
	(c) Provisions		
	(d) Current Tax Liabilities (net)	160.45	119.03
	Total Equity and Liabilities	16246.37	14307.64

For GODAVARI DRUGS LIMITED


Mohit Jaju

Wholetime Director & CFO

DIN: 03405414



Place: Secunderabad


Date : 14.11.2025


GODAVARI DRUGS LIMITED
CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER, 2025

Rupees in lakhs

Particulars	Period ended 30.09.2025 (Un Audited)	Yeare ended 31.03.2025 (Audited)
A. Cash Flow from Operating Activities		
Profit before Depreciation, Interest and Tax	554.45	1,280.50
Less : Other Income considered separately	(64.76)	(97.72)
Net	489.69	1,182.78
(Increase) / Decrease in Inventories	(830.17)	(729.09)
(Increase) / Decrease in Receivables	53.55	1,709.97
(Increase) / Decrease in short term loans & advances	(194.80)	(34.06)
Increase / (Decrease) in Current Liabilities including current tax lia	1,091.03	(1,010.00)
Total A	609.30	1,119.60
B. Cash Flow from Investing Activities		
(Increase)/Decrease in Fixed assets	(1,094.93)	(1,999.81)
(Increase)/Decrease in Non current assets	(1.20)	(49.12)
Other Income	64.76	97.72
Total B	(1,031.37)	(1,951.21)
C. Cash Flow from Financing Activities		
Increase/(Decrease) in Long Term Borrowings	596.63	1,272.78
Increase/(Decrease) in Long Term Provisions	8.72	7.07
Interest Paid	(191.30)	(473.20)
Total C	414.05	806.65
D. Net Increase/(Decrease) in cash and cash equivalents [A+B+C]	(8.02)	(24.96)
Cash and cash equivalents at the beginning of the year	237.33	262.29
Cash and cash equivalents at the end of the Period	229.31	237.33
Increase/(-)Decrease	(8.02)	(24.96)

Place: Secunderabad
Date : 14.11.2025

For GODAVARI DRUGS LIMITED

Mohit Jaju
Wholetime Director & CFO
DIN: 03405414



Independent Auditor's Review Report on Standalone unaudited six months and quarter ended 30.09.2025 financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
Godavari Drugs Limited
Secunderabad.

We have reviewed the accompanying statement of unaudited standalone financial results of Godavari Drugs Limited (the Company) for the six months and quarter ended 30th September 2025 (the statement). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepare policies hance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ayyadevara & Co.,
Chartered Accountants
FRN: 00278S



Ayyadevara Srinivas
Proprietor
ICAI Membership No. 028803
Hyderabad, November 14, 2025
UDIN: 25028803BMUJUP6666

